Exagen Appoints Dr. Michael Mahler as Chief Scientific Officer
Exagen Inc. (Nasdaq: XGN), a leader in autoimmune diagnostic solutions, expresses its excitement in welcoming Dr. Michael Mahler as the new Chief Scientific Officer. Dr. Mahler's robust background in immunology, alongside a focus on autoimmune research, will be invaluable in Exagen's mission to advance the diagnosis and treatment of autoimmune diseases.
Dr. Mahler earned his Ph.D. from the Institute of Molecular Genetics at the University of Heidelberg in Germany. During his doctoral studies, Dr. Mahler collaborated with respected figures in the field at the Scripps Research Institute, further enriching his understanding of autoimmune research. He also fostered a collaborative relationship with Dr. Marvin J. Fritzler, a well-established thought leader whose work encompasses a broad spectrum of autoantigen biology and innovative diagnostic methods.
Dr. Mahler's Impact on Diagnostic Innovation
Throughout his distinguished career, Dr. Mahler has made significant contributions in various diagnostic companies. His most recent role was Senior Vice President of Research Development and Business Development at Werfen, where he pioneered numerous innovative diagnostic solutions and discovered several new autoantigens. He has authored over 300 peer-reviewed publications and holds numerous patents, driving advancements in the accurate diagnosis of autoimmune diseases.
Strengthening Exagen’s Mission
John Aballi, President and CEO of Exagen, expressed enthusiasm about Dr. Mahler joining the team. "His extensive knowledge in autoimmune research and his dedication to scientific progress will enhance our diagnostic capabilities and ultimately improve patient care," he stated. In his new role, Dr. Mahler aims to lead strategic initiatives that focus on improving precision diagnostics for autoimmune conditions.
Optimizing Patient Outcomes
Dr. Mahler shared his excitement about joining Exagen, highlighting the company’s innovative landscape and commitment to revolutionizing autoimmune disease management. “I look forward to merging my experience with the patient-centered philosophy established by Exagen's leadership,” he commented enthusiastically.
About Exagen Inc.
Exagen Inc. (Nasdaq: XGN) specializes in transformative autoimmune diagnostics. Its mission revolves around providing clarity in decision-making for autoimmunities, ensuring better clinical outcomes through an avant-garde testing portfolio. The leading product, AVISE CTD, allows clinicians to diagnose complex autoimmune disorders such as lupus, rheumatoid arthritis, and Sjögren’s disease more effectively and accurately. Exagen’s laboratory is dedicated to the testing of rheumatic diseases, providing timely and precise results backed by a comprehensive range of AVISE-branded tests aimed at disease diagnosis, prognosis, and monitoring.
With a steadfast commitment to research, innovation, education, and patient-centric approaches, Exagen seeks to overcome the multifaceted challenges associated with autoimmune disease management.
Frequently Asked Questions
Who is Dr. Michael Mahler?
Dr. Michael Mahler is the newly appointed Chief Scientific Officer at Exagen Inc., bringing extensive expertise in immunology and autoimmune research.
What is the main goal of Dr. Mahler at Exagen?
Dr. Mahler will focus on enhancing precision diagnostics for autoimmune diseases and supporting the development of innovative tools that improve patient outcomes.
What does Exagen specialize in?
Exagen specializes in autoimmune diagnostics, providing advanced testing solutions for chronic autoimmune conditions, improving the accuracy and timeliness of diagnoses.
What is the AVISE CTD product?
The AVISE CTD is Exagen's flagship product that assists clinicians in diagnosing complex autoimmune diseases such as lupus and rheumatoid arthritis.
How can patients benefit from Exagen's services?
Patients can benefit from Exagen’s innovative diagnostic solutions which enable early and accurate diagnosis of autoimmune diseases, leading to better treatment strategies.
